Leiden (The Netherlands, 01.07.2021) – As of 1 July 2021, the Supervisory Board of the HAL Allergy Group has appointed Alex Huybens as Chief Executive Officer (CEO) and Member of the Board of HAL Allergy Holding B.V., as well as CEO of HALIX B.V.
Telephone counseling for all hospital staff members in the regions of Lombardy, Emilia Romagna, Veneto, Piedmont
Rome, Italy, (March 26, 2020) – Today, HAL Allergy S.r.l. announced the start of its ‘Prima Linea’ initiative offering telephone counseling for the highly committed hospital staff, who are engaged in the daily fight with the coronavirus in the most affected regions of Italy.
We are very pleased to announce that the Supervisory Board has appointed Dr. Hans van Schijndel as Member of the Board of HAL Allergy Holding B.V. in the position of Chief Research & Development Officer (Chief R&D Officer) as of 1 February 2020.
Registration of SUBLIVAC® Birch and SUBLIVAC® Trees 40.000 AUN/ml in Germany accomplished
Leiden, the Netherlands (14 August 2018) – HAL Allergy B.V. today announced the registration of SUBLIVAC® Birch 40.000 AUN/ml and SUBLIVAC® Trees 40.000 AUN/ml in Germany. These are the first marketing authorisations granted by the Paul Ehrlich Institute following the German Therapieallergene‑Verordnung (TAV).